During the recent session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares were 4.64 million, with the beta value of the company hitting 0.87. At the last check today, the stock’s price was $6.61, reflecting an intraday gain of 0.46% or $0.03. The 52-week high for the RXRX share is $12.36, that puts it down -86.99 from that peak though still a striking 15.28% gain since the share price plummeted to a 52-week low of $5.60. The company’s market capitalization is $2.66B, and the average trade volume was 23.65 million shares over the past three months.
Recursion Pharmaceuticals Inc (RXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. RXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.52.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Recursion Pharmaceuticals Inc (RXRX) registered a 0.46% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.46% in intraday trading to $6.61, hitting a weekly high. The stock’s 5-day price performance is -13.82%, and it has moved by -13.14% in 30 days. Based on these gigs, the overall price performance for the year is -46.26%.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 39.91% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $12 respectively. As a result, RXRX is trading at a discount of -81.54% off the target high and 9.23% off the low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 62.88% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 18.12M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 19.78M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 13.79M and 14.42M respectively. In this case, analysts expect current quarter sales to grow by 31.34% and then jump by 37.22% in the coming quarter.
RXRX Dividends
Recursion Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
The next largest institutional holding, with 26.59 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 10.9787% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $199.42 million.
Also, the Mutual Funds coming in first place with the largest holdings of Recursion Pharmaceuticals Inc (RXRX) shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. Data provided on Dec 31, 2024 indicates that ARK ETF Tr-ARK Innovation ETF owns about 18.28 shares. This amounts to just over 4.63 percent of the company’s overall shares, with a $121.27 million market value. The same data shows that the other fund manager holds slightly less at 11.51, or about 2.91% of the stock, which is worth about $76.35 million.
